Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs)

References

• Aldoss IT, Tashi T, Ganti AK. (2009). Seliciclib in malignancies. Expert Opin Investig Drugs 18:1957–65
   PubMed Web of Science ®Google Scholar
• Allen JD, van Loevezijn A, Lakhai JM, et al. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–25
   PubMed Web of Science ®Google Scholar
• Amant F, Van Calsteren K, Halaska MJ, et al. (2012). Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 13:256–64
   PubMed Web of Science ®Google Scholar
• An R, Hagiya Y, Tamura A, et al. (2009). Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res 26:449–58
   PubMed Web of Science ®Google Scholar
• Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. (2007). Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood–brain barrier. J Neurochem 102:1749–57
   PubMed Web of Science ®Google Scholar
• Carter AM. (2007). Animal models of human placentation – a review. Placenta 28(Suppl. A):S41–7
   PubMed Web of Science ®Google Scholar
• Ceckova M, Libra A, Pavek P, et al. (2006). Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33:58–65
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu AM. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793–807
   PubMed Web of Science ®Google Scholar
• Cicenas J, Valius M. (2011). The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137:1409–18
   PubMed Web of Science ®Google Scholar
• Cihalova D, Hofman J, Ceckova M, Staud F. (2013). Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One 8:e83467
   Google Scholar
• Cygalova LH, Hofman J, Ceckova M, Staud F. (2009). Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 331:1118–25
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. (2010). MRP2 mediated drug–drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 386:216–20
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Cao J, et al. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171–9
   PubMed Web of Science ®Google Scholar
• de Bruin M, Miyake K, Litman T, et al. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117–26
   PubMed Web of Science ®Google Scholar
• Dhillon S. (2015). Palbociclib: first global approval. Drugs 75:543–51
   PubMed Web of Science ®Google Scholar
• Draper MP, Martell RL, Levy SB. (1997). Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 75:810–15
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Fanucchi A, et al. (2003). Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 23:5225–9
   PubMed Web of Science ®Google Scholar
• Gedeon C, Koren G. (2006). Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 27:861–8
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM. (2013). Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther 94:3–9
   PubMed Web of Science ®Google Scholar
• Gollapudi S, Kim CH, Tran BN, et al. (1997). Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 40:150–8
   PubMed Web of Science ®Google Scholar
• Golstein PE, Boom A, van Geffel J, et al. (1999). P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch 437:652–60
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58
   PubMed Web of Science ®Google Scholar
• Gray NS, Wodicka L, Thunnissen AM, et al. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533–8
   PubMed Web of Science ®Google Scholar
• Hahnova-Cygalova L, Ceckova M, Staud F. (2011). Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev 43:53–68
   PubMed Web of Science ®Google Scholar
• Hofman J, Ahmadimoghaddam D, Hahnova L, et al. (2012). Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res 65:312–19
   PubMed Web of Science ®Google Scholar
• Hofman J, Kucera R, Cihalova D, et al. (2013). Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One 8:e75520
   Google Scholar
• Hochegger H, Takeda S, Hunt T. (2008). Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9:910–16
   PubMed Web of Science ®Google Scholar
• Holcakova J, Muller P, Tomasec P, et al. (2014). Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy. PLoS One 9:e89228
   Google Scholar
• Holcakova J, Tomasec P, Bugert JJ, et al. (2010). The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother 20:133–42
   PubMedGoogle Scholar
• Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. (1993). In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–602
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ikegami Y, Sano K, et al. (2006). Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des 12:313–25
   PubMed Web of Science ®Google Scholar
• Jorda R, Paruch K, Krystof V. (2012). Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres. Curr Pharm Des 18:2974–80
   PubMed Web of Science ®Google Scholar
• Krystof V, Lenobel R, Havlicek L, et al. (2002). Synthesis and biological activity of olomoucine II. Bioorg Med Chem Lett 12:3283–6
   PubMed Web of Science ®Google Scholar
• Krystof V, McNae IW, Walkinshaw MD, et al. (2005). Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci 62:1763–71
   PubMed Web of Science ®Google Scholar
• Krystof V, Uldrijan S. (2010). Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11:291–302
   PubMed Web of Science ®Google Scholar
• Loibl S. (2008). New therapeutic options for breast cancer during pregnancy. Breast Care (Basel) 3:171–6
   PubMed Web of Science ®Google Scholar
• Monaco EA, III Beaman-Hall CM, Mathur A, Vallano ML. (2004). Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem Pharmacol 67:1947–64
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Saito H, Ikegami Y, et al. (2006). Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett 234:81–9
   PubMed Web of Science ®Google Scholar
• Novotna M, Libra A, Kopecky M, et al. (2004). P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol 18:785–92
   PubMed Web of Science ®Google Scholar
• Pavlidis NA. (2002). Coexistence of pregnancy and malignancy. Oncologist 7:279–87
   PubMed Web of Science ®Google Scholar
• Rajnai Z, Mehn D, Beery E, et al. (2010). ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 38:2000–6
   PubMed Web of Science ®Google Scholar
• Saito H, Hirano H, Nakagawa H, et al. (2006). A new strategy of high-speed screening and quantitative structure–activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317:1114–24
   PubMed Web of Science ®Google Scholar
• Shapiro GI. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–83
   PubMed Web of Science ®Google Scholar
• Shepard RL, Cao J, Starling JJ, Dantzig AH. (2003). Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121–5
   PubMed Web of Science ®Google Scholar
• Staud F, Ceckova M. (2015). Regulation of drug transporter expression and function in the placenta. Expert Opin Drug Metab Toxicol 11:533–55
   PubMed Web of Science ®Google Scholar
• Staud F, Ceckova M, Micuda S, Pavek P. (2010). Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596:199–222
   PubMedGoogle Scholar
• Staud F, Cerveny L, Ceckova M. (2012). Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target 20:736–63
   PubMed Web of Science ®Google Scholar
• Staud F, Pavek P. (2005). Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720–5
   PubMed Web of Science ®Google Scholar
• Staud F, Vackova Z, Pospechova K, et al. (2006). Expression and transport activity of breast cancer resistance protein (BABCG/ABCG2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53–62
   PubMed Web of Science ®Google Scholar
• Stensheim H, Moller B, van Dijk T, Fossa SD. (2009). Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 27:45–51
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–34
   PubMed Web of Science ®Google Scholar
• Van Calsteren K, Heyns L, De Smet F, et al. (2010). Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 28:683–9
   PubMed Web of Science ®Google Scholar
• Villerbu N, Gaben AM, Redeuilh G, Mester J. (2002). Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer 97:761–9
   PubMed Web of Science ®Google Scholar
• Yokooji T, Murakami T, Ogawa K, et al. (2005). Modulation of intestinal transport of 2,4-dinitrophenyl-S-glutathione, a multidrug resistance-associated protein 2 substrate, by bilirubin treatment in rats. J Pharm Pharmacol 57:579–85
   PubMed Web of Science ®Google Scholar
• Yu XQ, Xue CC, Wang G, Zhou SF. (2007). Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr Drug Metab 8:787–802
   PubMed Web of Science ®Google Scholar